- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
Profile
- Financials
Cytokinetics (CYTK)
Company Profile
| Quarter (USD) | Sep 25 | Jun 25 | Mar 25 | Dec 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 228.58 mm | 228.58 mm | 228.58 mm | 228.58 mm | 228.58 mm | 228.58 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 55.59 mm | 47.74 mm | 35.84 mm | 36.08 mm |
| Cash used (since last report) | n/a | n/a | 77.65 mm | 66.70 mm | 50.06 mm | 50.40 mm |
| Cash remaining | n/a | n/a | 150.92 mm | 161.88 mm | 178.52 mm | 178.18 mm |
| Runway (months of cash) | n/a | n/a | 2.7 | 3.4 | 5.0 | 4.9 |
| 13F holders | Current |
|---|---|
| Total holders | 350 |
| Opened positions | 49 |
| Closed positions | 55 |
| Increased positions | 119 |
| Reduced positions | 131 |
| 13F shares | Current |
|---|---|
| Total value | 5.48 tn |
| Total shares | 139.65 mm |
| Total puts | 1.83 mm |
| Total calls | 3.42 mm |
| Total put/call ratio | 0.5 |
| Largest owners | Shares | Value |
|---|---|---|
| BlackRock | 15.47 mm | $727.68 bn |
| Vanguard | 11.92 mm | $560.52 bn |
| FMR | 10.79 mm | $507.78 bn |
| T. Rowe Price Investment Management | 10.75 mm | $505.78 mm |
| Wellington Management | 7.89 mm | $371.08 bn |
| STT State Street | 6.17 mm | $290.11 bn |
| Eastern Capital | 3.06 mm | $64.35 mm |
| Geode Capital Management | 2.84 mm | $133.69 bn |
| Biotechnology Value Fund L P | 2.73 mm | $54.56 mm |
| RTW Investments | 2.72 mm | $128.00 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 5 Nov 25 | Robert I Blum | Common Stock | Gift | Dispose G | No | No | 0 | 2,000 | 0.00 | 356,108 |
| 4 Nov 25 | Fady Ibraham Malik | Common Stock | Sell | Dispose S | No | No | 59.55 | 2,295 | 136.67 k | 140,610 |
| 4 Nov 25 | Fady Ibraham Malik | Common Stock | Option exercise | Acquire M | No | No | 10.6 | 2,295 | 24.33 k | 142,905 |
| 4 Nov 25 | Fady Ibraham Malik | Incentive Stock Option Common Stock | Option exercise | Dispose M | No | No | 10.6 | 2,295 | 24.33 k | 6,600 |
| 30 Oct 25 | Robert I Blum | Common Stock | Sell | Dispose S | No | No | 62.86 | 5,000 | 314.30 k | 358,108 |
| 27 Oct 25 | Wendell Wierenga | Common Stock | Sell | Dispose S | No | No | 58.68 | 4,375 | 256.73 k | 32,444 |
| 27 Oct 25 | Wendell Wierenga | Common Stock | Option exercise | Acquire M | No | No | 10 | 4,375 | 43.75 k | 36,819 |
| 27 Oct 25 | Wendell Wierenga | NQSO Common Stock | Option exercise | Dispose M | No | No | 10 | 4,375 | 43.75 k | 0 |
| 21 Oct 25 | Fady Ibraham Malik | Common Stock | Sell | Dispose S | No | No | 58.22 | 2,105 | 122.55 k | 140,610 |
| 21 Oct 25 | Fady Ibraham Malik | Common Stock | Option exercise | Acquire M | No | No | 10.6 | 2,105 | 22.31 k | 142,715 |